AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Phase 2

Completed

Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib

First Posted Date: 2017-08-04

Last Posted Date: 2024-10-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 154

Registration Number: NCT03239340

Locations: 🇪🇸
Research Site, Sevilla, Spain

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Phase 1

Completed

Conditions: Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Interventions: Drug: Standard Arm - Fulvestrant
Drug: AZD9496

First Posted Date: 2017-08-02

Last Posted Date: 2020-02-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 49

Registration Number: NCT03236974

Locations: 🇬🇧
Research Site, Sutton In Ashfield, United Kingdom

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MEDI0382 high dose
Drug: Placebo
Drug: MEDI0382 low dose
Drug: MEDI0382 mid dose
Drug: Liraglutide

First Posted Date: 2017-08-01

Last Posted Date: 2020-08-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 834

Registration Number: NCT03235050

Locations: 🇸🇰
Research Site, Zilina, Slovakia

Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA

Completed

Conditions: Ovarian Cancer

First Posted Date: 2017-07-25

Last Posted Date: 2019-06-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 446

Registration Number: NCT03229122

Locations: 🇯🇵
Research Site, Yamagata, Japan

A Study of LY3314814 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3314814
Drug: [13C415N3] LY3314814

First Posted Date: 2017-07-19

Last Posted Date: 2019-10-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT03222427

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Osimertinib

First Posted Date: 2017-07-18

Last Posted Date: 2021-09-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 156

Registration Number: NCT03219970

Locations: 🇨🇳
Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
🇨🇳
Prince of wales hospital, Hong Kong, China
🇨🇳
Queen Mary Hospital, Hong Kong, China

and more 1 locations

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Phase 1

Terminated

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: AZD2811
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2017-07-14

Last Posted Date: 2022-04-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 50

Registration Number: NCT03217838

Locations: 🇦🇺
Research Site, Melbourne, Australia

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Phase 1

Terminated

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)

Interventions: Drug: AZD5991 + Venetoclax
Drug: AZD5991

First Posted Date: 2017-07-14

Last Posted Date: 2022-09-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT03218683

Locations: 🇺🇸
Research Site, Houston, Texas, United States

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Phase 1

Completed

Conditions: Healthy Subjects in Fasted and Fed State

Interventions: Drug: Dapagliflozin/metformin XR 5/500mg
Drug: Dapagliflozin/metformin XR 10/1000mg
Drug: Dapagliflozin/metformin XR 5/500 mg

First Posted Date: 2017-07-13

Last Posted Date: 2018-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 284

Registration Number: NCT03216278

Locations: 🇧🇷
Research Site, Aparecida de Goiania, Brazil

AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer Male Subjects

Interventions: Drug: [11C]AZD1390

First Posted Date: 2017-07-12

Last Posted Date: 2018-02-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT03215381

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Home Terms & Conditions Privacy Policy